onr:"swepub:oai:lup.lub.lu.se:f1abcd5d-a4e3-4ca0-a932-fa8f1f424ef9"
Sökning: onr:"swepub:oai:lup.lub.lu.se:f1abcd5d-a4e3-4ca0-a932-fa8f1f424ef9" > Is there a role for...
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
- Albertsson-Lindblad, AlexandraLund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumörmikromiljö,Institutionen för kliniska vetenskaper, Lund,Lymfom - Klinisk forskning,Forskargrupper vid Lunds universitet,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Tumor microenvironment,Department of Clinical Sciences, Lund,Lymphoma - Clinical Research,Lund University Research Groups,Skåne University Hospital (författare)
Is there a role for immunomodulatory drugs in the treatment of mantle cell lymphoma?
- Artikel/kapitelEngelska2019
Förlag, utgivningsår, omfång ...
- 2019
Nummerbeteckningar
- LIBRIS-ID:oai:lup.lub.lu.se:f1abcd5d-a4e3-4ca0-a932-fa8f1f424ef9
- https://lup.lub.lu.se/record/f1abcd5d-a4e3-4ca0-a932-fa8f1f424ef9URI
Kompletterande språkuppgifter
- Språk:engelska
- Sammanfattning på:engelska &svenska
Ingår i deldatabas
- SwePubSwePub
Klassifikation
Anmärkningar
- Although survival has improved in patients with mantle cell lymphoma (MCL) during the last two decades, thanks to intensified approach upfront and with anti-CD20 targeted treatment, the disease is still regarded as incurable and for the elderly/unfit patient population, there is need for more tolerable and effective treatment options. Immunomodulatory drugs (IMiDs) have demonstrated activity in MCL and could be regarded as attractive components of combinatory regimens for MCL, in light of their broad spectrum of activity and the potency to synergize with monoclonal antibody treatment. This review focus on the role of lenalidomide (L) as single agent in R/R MCL and in combinatory regimens. To date, one can conclude that L is an active agent in MCL, preferably when combined with anti-CD20 antibody, and may have a role as upfront treatment of elderly/unfit patients. Moreover, regimens including lenalidomide in combination with immunochemotherapy and in chemo-free regimens have shown activity, albeit associated with an increased risk of dose-limiting toxicity in untreated patient populations. Randomized trials evaluating the addition of L upfront, and phase I/II trials on L combined with other novel agents such as BTK- and bcl-2 inhibitors are underway and will further bring insight into the role of IMiDs in MCL.
- Although survival has improved in patients with mantle cell lymphoma (MCL) during the last two decades, thanks to intensified approach upfront and with anti-CD20 targeted treatment, the disease is still regarded as incurable and for the elderly/unfit patient population, there is need for more tolerable and effective treatment options. Immunomodulatory drugs (IMiDs) have demonstrated activity in MCL and could be regarded as attractive components of combinatory regimens for MCL, in light of their broad spectrum of activity and the potency to synergize with monoclonal antibody treatment. This review focus on the role of lenalidomide (L) as single agent in R/R MCL and in combinatory regimens. To date, one can conclude that L is an active agent in MCL, preferably when combined with anti-CD20 antibody, and may have a role as upfront treatment of elderly/unfit patients. Moreover, regimens including lenalidomide in combination with immunochemotherapy and in chemo-free regimens have shown activity, albeit associated with an increased risk of dose-limiting toxicity in untreated patient populations. Randomized trials evaluating the addition of L upfront, and phase I/II trials on L combined with other novel agents such as BTK- and bcl-2 inhibitors are underway and will further bring insight into the role of IMiDs in MCL.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
- Jerkeman, MatsLund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumörmikromiljö,Institutionen för kliniska vetenskaper, Lund,Lymfom - Klinisk forskning,Forskargrupper vid Lunds universitet,Onkologi övergripande,Institutionen för kliniska vetenskaper, Lund,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Tumor microenvironment,Department of Clinical Sciences, Lund,Lymphoma - Clinical Research,Lund University Research Groups,Oncology corporate,Department of Clinical Sciences, Lund,Skåne University Hospital(Swepub:lu)onk-mje (författare)
- Medicinsk onkologiSektion I (creator_code:org_t)
Sammanhörande titlar
- Ingår i:Annals of Lymphoma3:2, s. 1-152616-2695
Internetlänk
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Albertsson-Lindb ...
- Jerkeman, Mats
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Cancer och onkol ...
- Artiklar i publikationen
- Annals of Lympho ...
- Av lärosätet
- Lunds universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
